Skip to main content

Table 3 The pharmacokinetic profile of ADU-1805 after a single dose exposure in NHPs

From: Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpoint

Dose

NCA half-life

Mid-range half-life

0.3 mg/kg

0.88 days

1.86 days

3 mg/kg

1.89 days

3.93 days

30 mg/kg

2.95 days

6.41 days